Menü
Menü
The INNOVATION CAMPUS BERLIN is a newly founded dynamic contract research institute with about 400 employees founded by the acquisition of a complete research unit from Bayer.
Decades of experience and top-notch expertise in the field of early pharmaceutical research combined with the spirit of a medium-sized, family owned company create an innovative campus of excellence for early Pharma research.
PRESS RELEASE | BERLIN | 19.04.2021
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and NUVISAN Innovation Campus Berlin (ICB) GmbH, a fully integrated contract research service provider for drug discovery and early development programs, today announced a non-exclusive license agreement granting NUVISAN ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
Read complete announcement:
↓ read complete announcement | PDF | 156 KB
COMPANY INFORMATION | BERLIN | NEU-ULM | 17.11.2020
Since the late 2019 onset of Coronavirus in Asia, NUVISAN’s management has been following the development of the disease, assessing its potential impact and anticipated precautionary measures to make sure employees are safe and to secure business continuity.
Read complete announcement:
↓ read complete announcement | PDF | 461 KB
The INNOVATION CAMPUS BERLIN research center comes with capabilities and capacities spanning the entire drug discovery value chain, including:
We add value to your project at every stage from disease biology to the patient by providing our Innovation Enabling Packages.
We have many years of experiences in the field of drug discovery in the pharmaceutical industry. We translate this expertise into evolving areas such as peptides, PROTACs and RNA-targeting small molecules.
From concept to proof-of-concept - wherever your need is. We join your project collaboratively and professionally. Based on our long-term pharmaceutical research experience we provide you with knowledge on cutting edge drug development, innovative research practice and how to advance your project optimally towards your goal.
On the 1st of July, the "INNOVATION CAMPUS BERLIN" (ICB), a subsidiary of NUVISAN GmbH/ Neu-Ulm officially opened. NUVISAN has taken over a large part of the Berlin-based pharmaceutical research unit, focused on the field of small molecule active ingredients, from Bayer AG and agreed on a strategic partnership.
↓read complete press release | PDF | 472 KB
We provide drug discovery services at first-rate industry standards.
From target idea to candidate - from candidate to patient.
We drive your idea forward.
